Phase III study of ruxolitinib in patients with Covid-19-associated acute respiratory distress syndrome on mechanical ventilation fails to meet primary endpoint

In the DEVENT study, mortality due to any cause through day 29 (primary endpoint) was 55.2% for the 5mg arm (vs 74.3% placebo; OR 0.42; 95% CI 0.171-1.023) and 51.8% for the 15mg arm (vs 69.6%; OR 0.46, 0.201-1.028).

Biospace Inc.